Becton, Dickinson completes $230 million acquisition of GeneOhm Sciences

By Angela McDaniels

Seattle, Feb. 14 - Becton, Dickinson and Co. has acquired GeneOhm Sciences Inc. for $230 million and will pay up to $25 million in additional incentives, according to a company news release.

The company said GeneOhm Sciences' molecular assays will allow Becton, Dickinson to move quickly into the emerging health care-associated infections field.

Ensuring prompt identification of bacteria, such as methicillin-resistant Staphylococcus aureus, lets physicians begin appropriate and directed drug therapy sooner and can significantly impact patient and economic outcomes, the company said.

Becton, Dickinson is a medical technology company based in Franklin Lakes, N.J., that makes and sells medical devices, instrumented systems and reagents.

GeneOhm Sciences is based in San Diego and develops molecular diagnostic testing for the rapid detection of bacterial organisms.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.